No label defined (Q32719)

From lgbtDB
Jump to navigation Jump to search
No description defined
  • Drug-drug interactions between gender-affirming hormone therapy and antiretrovirals for treatment/prevention of HIV.
Language Label Description Also known as
English
No label defined
No description defined
  • Drug-drug interactions between gender-affirming hormone therapy and antiretrovirals for treatment/prevention of HIV.

Statements

title
Drug-drug interactions between gender-affirming hormone therapy and antiretrovirals for treatment/prevention of HIV. (English)
1 reference
stated in
PubMed
abstract
Transgender persons face a greater burden of HIV compared to cisgender counterparts. (English)
series ordinal
1
copyright statement
© 2024 The Author. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. (English)
publisher
John Wiley & Sons
on behalf of
British Pharmacological Society
date copyrighted
2024
rights holder
Q31315
1 reference
stated in
PubMed
Concerns around drug-drug interactions (DDIs) have been cited as reasons for lower engagement in HIV care and lower pre-exposure prophylaxis (PrEP) uptake among transgender populations. (English)
series ordinal
2
copyright statement
© 2024 The Author. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. (English)
publisher
John Wiley & Sons
on behalf of
British Pharmacological Society
date copyrighted
2024
rights holder
Q31315
1 reference
stated in
PubMed
It is therefore imperative for hormone therapy, PrEP and antiretroviral therapy providers to understand the DDI potential between these therapies. (English)
series ordinal
3
copyright statement
© 2024 The Author. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. (English)
publisher
John Wiley & Sons
on behalf of
British Pharmacological Society
date copyrighted
2024
rights holder
Q31315
1 reference
stated in
PubMed
Studies of tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) PrEP with feminizing hormone therapies (FHTs) show reduced plasma tenofovir concentrations, but intracellular concentrations of tenofovir-diphosphate are not reduced. (English)
series ordinal
4
copyright statement
© 2024 The Author. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. (English)
publisher
John Wiley & Sons
on behalf of
British Pharmacological Society
date copyrighted
2024
rights holder
Q31315
1 reference
stated in
PubMed
Efficacy of PrEP is expected to be maintained despite this interaction. (English)
series ordinal
5
copyright statement
© 2024 The Author. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. (English)
publisher
John Wiley & Sons
on behalf of
British Pharmacological Society
date copyrighted
2024
rights holder
Q31315
1 reference
stated in
PubMed
Masculinizing hormone therapies have no effect on tenofovir concentrations but may increase FTC to a nonclinically relevant extent. (English)
series ordinal
6
copyright statement
© 2024 The Author. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. (English)
publisher
John Wiley & Sons
on behalf of
British Pharmacological Society
date copyrighted
2024
rights holder
Q31315
1 reference
stated in
PubMed
No interactions between FHT and cabotegravir or tenofovir alafenamide have been demonstrated. (English)
series ordinal
7
copyright statement
© 2024 The Author. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. (English)
publisher
John Wiley & Sons
on behalf of
British Pharmacological Society
date copyrighted
2024
rights holder
Q31315
1 reference
stated in
PubMed
Administration of TDF/FTC PrEP has no effect on hormone levels in transmen or transwomen. (English)
series ordinal
8
copyright statement
© 2024 The Author. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. (English)
publisher
John Wiley & Sons
on behalf of
British Pharmacological Society
date copyrighted
2024
rights holder
Q31315
1 reference
stated in
PubMed
PrEP is expected to be effective and safe in transpersons and should be provided to high-risk individuals regardless of gender affirming hormone use. (English)
series ordinal
9
copyright statement
© 2024 The Author. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. (English)
publisher
John Wiley & Sons
on behalf of
British Pharmacological Society
date copyrighted
2024
rights holder
Q31315
1 reference
stated in
PubMed
Enzyme inducing/inhibiting antiretroviral therapy may decrease or increase, respectively, the concentrations of FHT and masculinizing hormone therapy. (English)
series ordinal
10
copyright statement
© 2024 The Author. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. (English)
publisher
John Wiley & Sons
on behalf of
British Pharmacological Society
date copyrighted
2024
rights holder
Q31315
1 reference
stated in
PubMed
Unboosted integrase inhibitors or enzyme neutral non-nucleoside reverse transcriptase inhibitors are not expected to affect and are not affected by gender affirming hormones and can be considered in transmen and transwomen. (English)
series ordinal
11
copyright statement
© 2024 The Author. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. (English)
publisher
John Wiley & Sons
on behalf of
British Pharmacological Society
date copyrighted
2024
rights holder
Q31315
1 reference
stated in
PubMed
Overlapping toxicities including weight gain, dyslipidaemia, cardiovascular disease and bone density effects should be considered, and antiretroviral modifications can be made to minimize toxicities. (English)
series ordinal
12
copyright statement
© 2024 The Author. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. (English)
publisher
John Wiley & Sons
on behalf of
British Pharmacological Society
date copyrighted
2024
rights holder
Q31315
1 reference
stated in
PubMed
Interactions between supportive care medications should be assessed to avoid chelation interactions and hyperkalaemia. (English)
series ordinal
13
copyright statement
© 2024 The Author. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. (English)
publisher
John Wiley & Sons
on behalf of
British Pharmacological Society
date copyrighted
2024
rights holder
Q31315
1 reference
stated in
PubMed
date published
October 2024
1 reference
stated in
PubMed
date issued
October 2024
1 reference
stated in
PubMed
volume
90
1 reference
stated in
PubMed
issue
10
1 reference
stated in
PubMed
page(s)
2366-2382
1 reference
stated in
PubMed
page start
2366
1 reference
stated in
PubMed
page end
2382
1 reference
stated in
PubMed
 
Retrieved from "https://lgbtdb.wikibase.cloud/w/index.php?title=Item:Q32719&oldid=191554"